BMO Capital Reiterates Outperform on C4 Therapeutics, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Etzer Darout has reiterated an Outperform rating on C4 Therapeutics (NASDAQ:CCCC) and maintained a $20 price target.
August 06, 2024 | 1:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BMO Capital analyst Etzer Darout has reiterated an Outperform rating on C4 Therapeutics and maintained a $20 price target.
The reiteration of an Outperform rating and the maintenance of a $20 price target by a reputable analyst can boost investor confidence in C4 Therapeutics, potentially leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100